Conservative Treatment of Catheter - Related Injections With Gentamicine/EDTA

Inclusion Criteria: * Adult patient (≥18 year-old); * LTIVC in place (TIVAP or single-line tunnelled catheter); * LTIVC is functional (it is possible to inject an infusate, but also to draw blood from the catheter); * LTIVC-related bloodstream infection defined by a positive qualitative paired blood culture with a differential time to positivity ≥ 2 hours (meaning that the culture of the blood drawn from the catheter is positive at least 2 hours before the culture of the blood drawn from a peripheral vein); * Mono microbial infection caused by coagulase-negative staphylococci, Enterobacteriaceae or Pseudomonas aeruginosa; * Bacterial strain is susceptible toward gentamicin; * Life expectancy ≥ 3 months; * Physician in charge of the patient agrees to perform a conservative treatment; * Calculated creatinine clearance ≥ 30 mL/min; * Patient's informed and written consent is collected. * For women of reproductive age: available beta-HCG dosage (with negative result) \< 72h. Non-inclusion criteria: A patient should not be included if he presents any of the following criteria: * Presence of any systemic complication (sepsis or septic shock, as defined by the sepsis-3 guidelines), or local complications (tunnel or port-pocket infection, thrombophlebitis, endocarditis, bone and joint infections related to the LTIVC-related BSI); * Allergy toward aminoglycosides * PICC-line or hemodialysis tunnelled catheter; LTIVC removal is planned within the following 3 months or LTIVC is not required for the management of the patient's underlying medical condition anymore; * Diagnosis of LTIVC-related bloodstream infection has been made more than 3 days ago (e.g. \>72 hours between the day the first blood culture drawn from the LTIVC is positive and screening visit); * Systemic treatment of LTIVC-related bloodstream infection includes aminoglycosides (defined as a recent (\<36 hours before screening visit) or ongoing systemic injection of aminoglycosides); * Low blood ionized calcium level (\<1,15 μmol/L) before injecting the first dose of genta-EDTA-Na2 lock; * Presence of prosthetic heart valve, pacemaker or implantable defibrillator; * The LTIVC has been inserted less than 14 days ago; * Available Count blood cells \< 72h with severe neutropenia (\<500 polymorphonuclear cells/mm3); * Subject with infection caused by Staphylococcus Aureus orCandida-spp; * The patient is not expected to remain in hospital for at least 7 days after inclusion. * The administration of the lock according to the protocol (24 hours/day for 48 hours and then at least 12 hours/24 hours for 5 to 8 days) is not possible. * Decision by the referring physician to prescribe a preventive lock following curative Gentamicin-EDTA treatment (secondary prevention), between the end of treatment (D6/D9) and the D40 follow-up visit. * Previous inclusion in a study or another therapeutic protocol requiring continuous use of the catheter * Pregnant and breastfeeding woman; * Protected adult subject. * Inability to perform a blood peripheral venous sampling Exclusion criteria A patient should be excluded if he presents any of the following criteria: * Presence of local or systemic complication seen on venous ultrasound performed between D2 and D5 or transthoracic echocardiography performed between Day 2 and Day 7 (D2-D7); * GFR \< 30 ml/min (between D0 and D6/9).